Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: Response by beta-agonist reversibility

Abstract This retrospective analysis of data from two multi-center, randomized, double-blind, parallel group studies compared the efficacy of fluticasone propionate/salmeterol (FSC) 250/50 mcg twice daily with ipratropium bromide/albuterol (IB/ALB) 36/206 mcg four times daily in albuterol-reversible...

Full description

Saved in:
Bibliographic Details
Published in:Pulmonary pharmacology & therapeutics 2008-08, Vol.21 (4), p.682-688
Main Authors: Bleecker, Eugene R, Emmett, Amanda, Crater, Glenn, Knobil, Katharine, Kalberg, Christopher
Format: Article
Language:English
Subjects:
Adrenergic beta-Agonists - pharmacology
Adrenergic beta-Agonists - therapeutic use
Aged
Albuterol
Albuterol - analogs & derivatives
Albuterol - pharmacology
Albuterol - therapeutic use
Albuterol, Ipratropium Drug Combination
Androstadienes - pharmacology
Androstadienes - therapeutic use
Area Under Curve
Beta-agonist
Bronchodilator Agents - pharmacology
Bronchodilator Agents - therapeutic use
Chronic obstructive pulmonary disease (COPD)
Drug Combinations
Female
Fluticasone propionate
Fluticasone-Salmeterol Drug Combination
Forced Expiratory Volume
Humans
Inhaled corticosteroid
Ipratropium
Ipratropium - pharmacology
Ipratropium - therapeutic use
Male
Medical Education
Middle Aged
Multicenter Studies as Topic
Pulmonary Disease, Chronic Obstructive - drug therapy
Pulmonary Disease, Chronic Obstructive - physiopathology
Pulmonary/Respiratory
Randomized Controlled Trials as Topic
Respiratory Function Tests
Retrospective Studies
Reversibility
Salmeterol
Severity of Illness Index
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract This retrospective analysis of data from two multi-center, randomized, double-blind, parallel group studies compared the efficacy of fluticasone propionate/salmeterol (FSC) 250/50 mcg twice daily with ipratropium bromide/albuterol (IB/ALB) 36/206 mcg four times daily in albuterol-reversible ( n =320 [44%]) and non-reversible ( n =399 [56%]) patients with COPD. In reversible and non-reversible patients, both treatments significantly increased FEV1 AUC0–6h from baseline and the magnitude of improvement was larger in reversible patients. FSC increased FEV1 AUC0–6h by 1.46±0.08 and 1.98±0.13 l-h at Day 1 and Week 8, respectively, in reversible patients, compared with 0.71±0.06 and 0.94±0.10 l-h in non-reversible patients ( p
ISSN:1094-5539
1522-9629
DOI:10.1016/j.pupt.2008.04.003